BBIO vs BCRX Stock Comparison
BBIO currently leads BCRX in this stock comparison, with AIQ scores of 64 vs 59. The clearest difference is momentum, while BCRX has the stronger value profile.
What is the main difference between BBIO and BCRX?
BBIO leads the current stock comparison as BridgeBio Pharma, Inc., with the clearest separation coming from momentum and the broader AIQ evidence mix.
AlgovestIQ AIQ Comparison
BridgeBio Pharma, Inc. vs BioCryst Pharmaceuticals, Inc.
BBIO leads
BBIO leads by 5 AIQ points, primarily on Momentum and Risk Resilience, having only recently taken the lead back from BCRX. Wall Street currently favors BCRX on target upside.
Fragile: 4 of 6 evidence groups support BBIO, the lead recently changed hands, and its current signal state is conflicted.
BridgeBio Pharma, Inc.
BioCryst Pharmaceuticals, Inc.
The Algovestiq AIQ Score currently favors BBIO over BCRX, 64 versus 59 as of Nov 15, 2026. BBIO's advantage is driven primarily by stronger momentum and risk resilience, while BCRX holds the stronger value profile. BBIO also shows the stronger technical structure relative to its 50-day moving average, though analyst target upside currently favors BCRX. 4 of 6 covered evidence groups favor BBIO today, and the comparison is rated Fragile on stability: the AIQ gap is narrow at 5 points. BBIO lead: Reversed — BCRX led by 10 AIQ points 30 sessions ago; BBIO now leads by 5.
Compare BridgeBio Pharma, Inc. and BioCryst Pharmaceuticals, Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.
Performance over time
Price return from daily closes; distributions are not included.
Price return comparison
Growth of $10,000, price only
Split-adjusted closes only. Distributions are excluded, which understates the return of any fund or stock that pays them.
Compare BBIO and BCRX against another ticker
Open a multi-ticker workspace without changing this focused pair page.
AIQ Factor Divergence
Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.
- Value55 vs 86BCRX +31
- Momentum69 vs 42BBIO +27
- Risk Resilience62 vs 55BBIO +7
- Quality66 vs 64Even
4 of 6 evidence groups favor BBIO. BBIO’s edge is concentrated in momentum and risk resilience; BCRX keeps a meaningful value edge.
What changed since the last close
Latest scored session 2026-11-13, compared against the prior scored session 2026-11-12.
Largest factor move: Quality +1
No signal started or stopped since the prior session; its 5 active signals are unchanged.
Largest factor move: Quality +1, not enough on its own to move the overall score.
No signal started or stopped since the prior session; its 4 active signals are unchanged.
BBIO's lead widened by 1 AIQ point in the latest session.
Deeper signal detail for each name lives on its own signals page — BBIO and BCRX both carry a full feed there.
The central trade-off
BBIO (BridgeBio Pharma, Inc.): the stronger current systematic profile, led by momentum and risk resilience.
BCRX (BioCryst Pharmaceuticals, Inc.): the counter-case, on value, valuation, analyst expectations — but at materially higher volatility, 45.2% against 39.1%.
The AIQ Score and Wall Street therefore point in different directions on this pair.
Which one fits your objective
The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.
Balanced
BBIOBBIO on the overall AIQ Score, which weights Quality and Value most heavily.
Growth
BBIOBBIO on combined revenue and EPS growth.
Value
BCRXBCRX on the peer-relative Value factor, by 31 points.
Momentum
BBIOBBIO on the Momentum factor, by 27 points.
Lower downside
BBIOBBIO on Risk Resilience, by 7 points.
Analyst upside
BCRXBCRX on implied upside to the consensus price target.
AIQ vs Wall Street
The model and the Street disagree here: AIQ favors BBIO, analyst targets favor BCRX. That disagreement is the most useful thing on this page.
| Measure | BBIO | BCRX | Note |
|---|---|---|---|
| Implied upside to target | +42% | +44.5% | BCRX has more room |
| Target dispersion | +62.1% | 0% | Lower is tighter analyst agreement |
| Consensus | Buy | Buy | Context, not a primary driver |
| Analysts covering | 22 | 11 | Higher coverage generally improves confidence |
The two are measuring different things. The AIQ Score reads current fundamentals, valuation, trend and risk; analyst targets price forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something already priced in — it is worth resolving before acting on either.
Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.
AIQ Agreement Matrix
4 of 6 covered evidence groups favor BBIO. A wide gap backed by one group is a weaker case than a narrow gap backed by five.
| Evidence group | Favors | Reading |
|---|---|---|
| AIQ Score | BBIO | 64 vs 59 |
| Fundamentals | BBIOon balance | revenue growth 44.9% vs -17.4%; EPS growth 46.2% vs -51.6%; TTM ROE 3.4% vs -9.5%; gross margin 93.5% vs 25.3%; operating margin -43.4% vs -30.1% — BBIO takes 4 of 5 decided legs, not all of them |
| Valuation | BCRX | Value 55 vs 86 |
| Technicals | BBIO | Price vs 50-day 11.9% vs -7.6%; vs 200-day 7.7% vs -13.5% |
| Risk Resilience | BBIO | Risk Resilience 62 vs 55 |
| Analyst expectations | BCRX | Target upside 42% vs 44.5% |
✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of BBIO and BCRX and are excluded from the count.
AIQ Decision Stability
The conclusion is sensitive to small changes. Treat the lead as provisional and watch the flip conditions below.
- The AIQ gap is narrow at 5 points. (argues the conclusion is provisional)
- The lead has already changed hands inside the comparison window. (argues the conclusion is provisional)
- The leader is throwing conflicting signals. (argues the conclusion is provisional)
- Analyst targets on the leader are widely dispersed. (argues the conclusion is provisional)
Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on BBIO.
How the comparison changed
120 daily snapshots · May 27 – Nov 13BBIO lead: Reversed — BCRX led by 10 AIQ points 30 sessions ago; BBIO now leads by 5.
- Today
- BBIO +5
- 64 vs 59
- 7 sessions ago
- Level
- 62 vs 62
- 30 sessions ago
- BCRX +10
- 50 vs 60
- 90 sessions ago
- BCRX +12
- 59 vs 71
The lead has not changed hands in this window.
AIQ Signal Divergence
Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.
2 bullish / 2 bearish / 1 neutral, conflicted
Only BBIO
- ADX Trend Strengthening — neutral, trend, medium horizon
- EMA Ribbon Expansion Bullish — bullish, trend, medium horizon
- Low Volume Rally Warning — bearish, volume, short horizon (0.38x)
- TRIX Bullish Signal — bullish, momentum, short horizon
0 bullish / 2 bearish / 2 neutral
Only BCRX
- ADX Trend Weakening — neutral, trend, medium horizon
- ATR Expansion - Breakout Mode — neutral, volatility, short horizon (4.55%)
- Downtrend Structure Active — bearish, trend, long horizon
Both carry 1 more signal that do not separate them: Death Cross Active.
BBIO leads the comparison while carrying a conflicted signal state, which is one reason the stability rating is not higher.
Price vs model alignment
Whether the latest session's price move confirms what the model did over the same session, or contradicts it.
Price and the AIQ Score both moved up over the latest session (price +0.17%, AIQ +1 points).
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price -0.91%, AIQ 0 points).
What would flip this result
A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.
- 1BCRX closes the Momentum gap — currently 27 points behind, the largest single contributor to BBIO's edge.
- 2BCRX's Death Cross Active resolves — a bearish trend rule currently active against it.
- 3BBIO's conflicting signal state resolves bearish — it currently carries 2 bullish and 2 bearish rules at once.
- 4A market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.
The full evidence
Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.
Fundamentals
BBIO leads on balance| Metric | BBIO | BCRX |
|---|---|---|
| Revenue growth (YoY) | 44.9% | -17.4% |
| EPS growth (YoY) | 46.2% | -51.6% |
| Gross margin | 93.5% | 25.3% |
| Operating margin | -43.4% | -30.1% |
| Return on equity (TTM) | 3.4% | -9.5% |
| Debt to equity | -1.5 | -2.08 |
Performance
BBIO leads 6 of 6 windows| Metric | BBIO | BCRX |
|---|---|---|
| 1 week (5 sessions) | 5.4% | -1% |
| 1 month (20 sessions) | 17.9% | -2.3% |
| 3 months (63 sessions) | -2% | -23.4% |
| 6 months (126 sessions) | 18.4% | -15.6% |
| Year to date | 2.4% | -2.4% |
| 1 year (252 sessions) | 18.2% | 6% |
Technicals
BBIO has the stronger structure| Metric | BBIO | BCRX |
|---|---|---|
| RSI (14) | 65 | 40.7 |
| ADX (14) | 38.9 | 15.2 |
| Price vs 50-day | 11.9% | -7.6% |
| Price vs 200-day | 7.7% | -13.5% |
| Volatility (1M, annualized) | 39.1% | 45.2% |
Risk
BBIO is the more resilient| Metric | BBIO | BCRX |
|---|---|---|
| Beta | 0.95 | 0.65 |
| Sharpe ratio | 0.55 | 0.36 |
| Sortino ratio | 0.84 | 0.56 |
| Max drawdown | -29.8% | -32.2% |
| Current drawdown | -13.2% | -31.5% |
| Annualized volatility | 44.1% | 48.1% |
| Value at risk (95%) | -4% | -4.1% |
Straight answers
Each answer is regenerated from the current snapshot, not written once and left to age.
Which is better, BBIO or BCRX?
On the Algovestiq AIQ Score, BBIO is the stronger of the two as of Nov 15, 2026, scoring 64 against BCRX's 59. The edge comes from momentum and risk resilience. BCRX is not without a case — it holds the better value profile, which matters more if that is the objective you are optimizing for. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.
Is BBIO or BCRX the better buy right now?
BBIO carries the stronger systematic profile as of Nov 15, 2026, and the comparison is rated Fragile — 4 of 6 covered evidence groups agree. A Fragile rating means the conclusion is sensitive: the AIQ gap is narrow at 5 points. Treat the lead as provisional.
Why does the AIQ Score favor BBIO over BCRX?
The composite weights Quality, Value, Momentum and Risk Resilience. BCRX leads Value by 31 points; BBIO leads Momentum by 27 points; BBIO leads Risk Resilience by 7 points. Where the two split, the factor with the larger weight carries the result.
Which has more analyst upside, BBIO or BCRX?
Analyst price targets imply +42% upside for BBIO and +44.5% for BCRX, so the Street currently favors BCRX. That points the opposite way to the AIQ Score, which favors BBIO. The two are measuring different things: the model reads current fundamentals, valuation, trend and risk; the Street is pricing forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something the analysts have already priced — it is the single most useful row on this page to investigate. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.
Which is better value, BBIO or BCRX?
BCRX is the better-valued of the two on the peer-relative Value factor. BCRX on the peer-relative Value factor, by 31 points. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.
Which has stronger growth, BBIO or BCRX?
BBIO on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.
Which has stronger momentum, BBIO or BCRX?
BBIO on the Momentum factor, by 27 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.
Which is riskier, BBIO or BCRX?
BBIO is the more resilient of the two, so the other name carries the higher downside risk. BBIO on Risk Resilience, by 7 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.
Is BBIO more profitable than BCRX?
The profitability evidence is mixed: gross margin 93.5% vs 25.3%; operating margin -43.4% vs -30.1%; ttm roe 3.4% vs -9.5%. BBIO leads on two measures and BCRX on one measure, and there is no single profitability composite that resolves the split — which of the two reads as "more profitable" depends on whether you weight pricing power or operating leverage.
Is BBIO's lead over BCRX getting stronger or weaker?
BBIO lead: Reversed — BCRX led by 10 AIQ points 30 sessions ago; BBIO now leads by 5. This is measured from 120 daily comparison snapshots between 2026-05-27 and 2026-11-13. The lead has not changed hands in that window.
What would change the BBIO vs BCRX verdict?
The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: BCRX closes the Momentum gap — currently 27 points behind, the largest single contributor to BBIO's edge; BCRX's Death Cross Active resolves — a bearish trend rule currently active against it; BBIO's conflicting signal state resolves bearish — it currently carries 2 bullish and 2 bearish rules at once; a market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.
What do the current signals say about BBIO and BCRX?
BBIO: 2 bullish / 2 bearish / 1 neutral, conflicted. BCRX: 0 bullish / 2 bearish / 2 neutral. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on BBIO is Death Cross Active (bearish, long horizon). On BCRX it is Death Cross Active (bearish, long horizon).
Compare BBIO and BCRX with others
Continue your research
This page answers which of the two. These answer the questions on either side of it.
How this comparison is scored
The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.
The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.
How to use side-by-side comparison →This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.